REMSleep Holdings Inc. reported a significant shift in its financial performance for the fiscal year ending December 31, 2025, as it transitioned from selling traditional CPAP machines to its newly launched DeltaWave product line. The company recognized revenue of $16,721 from DeltaWave sales, a stark decline from $117,185 in revenue generated from CPAP machines in 2024. The cost of goods sold for DeltaWave was $12,707, resulting in a gross margin of $4,014. This change reflects a strategic pivot aimed at addressing compliance issues associated with traditional CPAP devices, which have a high discontinuation rate among users.
Operating expenses for REMSleep Holdings increased significantly, totaling $2,771,786 in 2025 compared to $811,586 in 2024. This rise was primarily driven by a substantial increase in compensation expenses, which soared to $2,269,500 from $143,000 the previous year. The increase was attributed to payments made to the former CEO and the issuance of preferred stock for non-cash compensation. Additionally, general and administrative expenses rose by 42.3% to $383,327, influenced by costs related to outside sales personnel and consulting services. The company reported a net loss of $3,020,300 for 2025, compared to a net loss of $1,077,997 in 2024.
In terms of operational developments, REMSleep Holdings has made strides in product development and market positioning. The company received FDA 510(k) approval for the DeltaWave product in January 2026, which broadens its indicated use beyond home-based therapy to institutional settings. The DeltaWave product is designed to improve patient comfort and compliance, addressing a critical issue in the sleep apnea market where many patients abandon CPAP therapy due to discomfort. The company is actively building a sales funnel and negotiating with hospital distributors to facilitate the product's launch.
The company’s financial health remains precarious, with an accumulated deficit of $18,291,056 as of December 31, 2025. Cash flow from operations showed a reduction in cash used, amounting to $502,829 compared to $683,057 in 2024. The company’s ability to continue operations is contingent upon securing additional financing, as indicated in its filings. The management has expressed uncertainty regarding its capacity to raise capital, which is critical for sustaining operations and achieving profitability.
Looking ahead, REMSleep Holdings aims to capture 10% of the sleep apnea market within the next year, leveraging the unique features of the DeltaWave product. The company plans to ramp up sales efforts in the second quarter of 2026, with expectations of positive initial customer reactions. However, the ongoing need for adequate financing and the successful execution of its operational strategies will be crucial for the company’s future viability and growth in the competitive sleep apnea treatment market.
About RemSleep Holdings Inc.
RemSleep Holdings, Inc. develops and markets sleep apnea treatment devices, notably the patented DeltaWave nasal pillow interface designed for improved comfort and compliance. The company focuses on innovative, minimally invasive respiratory solutions, targeting sleep clinics, healthcare providers, and patients. Its business model emphasizes product development, regulatory approval, and strategic marketing within the growing sleep disorder market, competing against major industry players through proprietary technology and product differentiation.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.